A contemporary analysis of palliative procedures in aborted pancreatoduodenectomy: Morbidity, mortality, and impact on future therapy.

[1]  Jeffrey W. Clark,et al.  Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX , 2019, Annals of surgery.

[2]  R. Andersson,et al.  Update on the management of pancreatic cancer: surgery is not enough. , 2015, World journal of gastroenterology.

[3]  M. D'Angelica,et al.  Operative procedures for unresectable pancreatic cancer: does operative bypass decrease requirements for postoperative procedures and in-hospital days? , 2012, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[4]  D. Jäger,et al.  Chemotherapy for pancreatic cancer. , 2019, Presse medicale.

[5]  M. Porembka,et al.  Quantitative weighting of postoperative complications based on the accordion severity grading system: demonstration of potential impact using the american college of surgeons national surgical quality improvement program. , 2010, Journal of the American College of Surgeons.

[6]  E. Kruse,et al.  Palliation in pancreatic cancer. , 2010, The Surgical clinics of North America.

[7]  R. Bold,et al.  An analysis of cost and clinical outcome in palliation for advanced pancreatic cancer. , 2005, American journal of surgery.

[8]  K. Lillemoe,et al.  Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial. , 1999, Annals of surgery.

[9]  M. Makary,et al.  Palliative Surgical Management of Patients with Unresectable Pancreatic Adenocarcinoma: Trends and Lessons Learned from a Large, Single Institution Experience , 2011, Journal of Gastrointestinal Surgery.

[10]  Y. Hiasa,et al.  Efficacy of chemotherapy in elderly patients with unresectable pancreatic cancer: a multicenter review of 895 patients , 2017, BMC Gastroenterology.

[11]  M. Falasca,et al.  Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies , 2017, International journal of molecular sciences.

[12]  J. Cameron,et al.  Surgical management of unresectable carcinoma of the pancreas. , 1982, Surgery.

[13]  H. Rasouli,et al.  Survival Rate and Complications of Palliative Bypass Surgery in Advanced Cancer of the Ampulla of Vater and Pancreatic Head , 2017 .

[14]  K. Lillemoe.  Current Management of Pancreatic Carcinoma , 1995, Annals of surgery.

[15]  Hai Hu,et al.  Predictors of Resectability and Survival in Patients with Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment with FOLFIRINOX. , 2017, Annals of surgery.

[16]  P. Macmathuna,et al.  Palliative biliary stents for obstructing pancreatic carcinoma. , 2006, The Cochrane database of systematic reviews.

[17]  V. Heinemann,et al.  Primary advanced unresectable pancreatic cancer. , 2008, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[18]  N. Fazio,et al.  Chemotherapy in pancreatic adenocarcinoma. , 2010, European review for medical and pharmacological sciences.

[19]  F. Poizat,et al.  Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a prospective cohort study , 2020, BMC Cancer.

[20]  D. Fraker,et al.  Surgical Palliation for Pancreatic Malignancy: Practice Patterns and Predictors of Morbidity and Mortality , 2014, Journal of Gastrointestinal Surgery.

[21]  I. Nomikos,et al.  Current Surgical Aspects of Palliative Treatment for Unresectable Pancreatic Cancer , 2011, Cancers.